secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001193125-25-184083
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics appoints Leiden Dworak as Principal Accounting Officer
-------------------------------------------------------------------------

- Appointment effective August 14, 2025; Dworak also serves as VP Finance since April 2022.
- Jason Amello ceases as Principal Accounting Officer but remains CFO and Principal Financial Officer.
- Dworak previously held the same PAO role from July 2023 to January 2024.
- 17 years biotech finance experience including VP Finance at AVROBIO and Director at Moderna.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312525184083/0001193125-25-184083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312525184083/d55649d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-184083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer